Recipharm has sold the solid dose manufacturing site at Fontaine-lès-Dijon, France to Astrea Pharma, the newly established contract development and manufacturing organization ( CDMO ) focused on small molecule oral solid and aseptic dosages.
BEIJING--(BUSINESS WIRE)--Pharmaron Beijing Co., Limited (Stock Code: 300759.SZ/3759.HK) (“Pharmaron”) announced today that it has acquired Aesica Pharmaceuticals Limited (“The Cramlington Site”) from Recipharm group.
The implementation of serialisation regulations in 2017 are among the opportunities for drugmakers to improve manufacturing efficiencies, says IT and engineering firm Zenith Technologies.
Novel business model set to streamline and speed products to market whilst reducing cost and complexity of development Bespak and Aesica are unveiling the industry’s first single source supply chain solution for drug delivery products incorporating formulation development, device design and development, drug and device manufacture, fill/finish and secondary packaging. This new business model has been brought to the market following Consort Medical’s acquisition of Aesica.
The initiative forms part of the company's commitment to renewable energy and safeguarding the environment. Aesica, the global pharmaceutical contract development and manufacturing organisation (CDMO), is pleased to announce its involvement in a renewable green initiative involving its UK, Cramlington site.
Aesica Gains FDA Approval for German Sites
Global Active Pharmaceutical Ingredients Market 2015-2019